0001415889-21-000362.txt : 20210121 0001415889-21-000362.hdr.sgml : 20210121 20210121171510 ACCESSION NUMBER: 0001415889-21-000362 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210119 FILED AS OF DATE: 20210121 DATE AS OF CHANGE: 20210121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JACOBSEN MICHAEL A CENTRAL INDEX KEY: 0001529087 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34475 FILM NUMBER: 21542886 MAIL ADDRESS: STREET 1: 201 ELLIOTT AVENUE WEST CITY: SEATTLE STATE: WA ZIP: 98119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OMEROS CORP CENTRAL INDEX KEY: 0001285819 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911663741 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 ELLIOTT AVENUE WEST CITY: SEATTLE STATE: WA ZIP: 98119 BUSINESS PHONE: 206-676-5000 MAIL ADDRESS: STREET 1: 201 ELLIOTT AVENUE WEST CITY: SEATTLE STATE: WA ZIP: 98119 4 1 form4-01212021_050101.xml X0306 4 2021-01-19 0001285819 OMEROS CORP OMER 0001529087 JACOBSEN MICHAEL A C/O OMEROS CORPORATION 201 ELLIOTT AVENUE WEST SEATTLE WA 98119 false true false false VP FINANCE AND CAO Common Stock 2021-01-19 4 S 0 9500 19.95 D 4000 D Common Stock 2021-01-20 4 M 0 10000 9.37 A 14000 D Stock Option (right to buy) 9.37 2021-01-20 4 M 0 10000 9.37 D 2023-09-24 Common Stock 30000 19188 D Open market sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2020, at which time the trading schedule, including sale periods, price and the number of shares to be sold, was established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. 25% of the total number of shares subject to this option vested on September 3, 2014, and the remaining shares subject to the option vested and became exercisable in equal monthly installments over the 36 months following the initial vesting date. On January 20, 2021, the reporting person paid the exercise price and exercised options to purchase 10,000 shares of the company's common stock. These shares have not been sold and are held for the account of the reporting person. /s/ Peter B. Cancelmo, Attorney-in-Fact 2021-01-21